A Pilot Trial of Thymalfasin (Tα1) to Treat Hospitalized Patients with Hypoxemia and Lymphocytopenia due to COVID-19 Infection.
J Infect Dis
; 2022 Sep 03.
Article
in English
| MEDLINE | ID: covidwho-2235518
ABSTRACT
BACKGROUND:
Thymosin-α-1 (Tα1) may be a treatment option for COVID-19, but efficacy and safety data remain limited.METHODS:
Prospective, open-label, randomized trial assessing preliminary efficacy and safety of thymalfasin (synthetic form of Tα1), compared with standard of care, among hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19.RESULTS:
49 patients were included in this analysis. Compared with control patients, the incidence of clinical recovery was higher for treated patients with either baseline low flow oxygen (subdistribution hazard ratio [SHR] 1.48; 95% CI 0.68-3.25) or baseline high flow oxygen (SHR 1.28; 95% CI 0.35-4.63), although neither were significant. Among patients with baseline low flow oxygen, treated patients, compared with control patients, had an average difference of 3.84 times more CD4+ T cells on Day 5 than on Day 1 (p = 0.0113). Nine serious adverse events among treated patients were deemed not related to Tα1.CONCLUSION:
Tα1 increases CD4+ T cell count among patients with baseline low flow oxygen support faster than standard of care and may have a role in the management of hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Infdis
Similar
MEDLINE
...
LILACS
LIS